Glioblastoma Multiforme (GBM) Treatment Market Size, Share and Forecast by 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Glioblastoma Multiforme (GBM) Treatment Market Size Analysis

Global Glioblastoma Multiforme (GBM) Treatment Market Introduction
By Treatment
1. Introduction
  1. Treatment By Value
2. Surgery
  1. By Value
3. Radiation Therapy
  1. By Value
4. Chemotherapy
  1. By Value
5. Targeted Therapy
  1. By Value
6. Tumor Treating Field (TTF) Therapy
  1. By Value
7. Immunotherapy
  1. By Value
By Drugs
1. Introduction
  1. Drugs By Value
2. Temozolomide
  1. By Value
3. Bevacizumab
  1. By Value
4. Lomustine
  1. By Value
5. Carmustine Wafers
  1. By Value
6. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Clinics
  1. By Value
4. Ambulatory Surgical Centers
  1. By Value

North America Market Analysis

Introduction
By Treatment
1. Introduction
  1. Treatment By Value
2. Surgery
  1. By Value
3. Radiation Therapy
  1. By Value
4. Chemotherapy
  1. By Value
5. Targeted Therapy
  1. By Value
6. Tumor Treating Field (TTF) Therapy
  1. By Value
7. Immunotherapy
  1. By Value
By Drugs
1. Introduction
  1. Drugs By Value
2. Temozolomide
  1. By Value
3. Bevacizumab
  1. By Value
4. Lomustine
  1. By Value
5. Carmustine Wafers
  1. By Value
6. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Clinics
  1. By Value
4. Ambulatory Surgical Centers
  1. By Value
U.S.
1. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Surgery
    1. By Value
  3. Radiation Therapy
    1. By Value
  4. Chemotherapy
    1. By Value
  5. Targeted Therapy
    1. By Value
  6. Tumor Treating Field (TTF) Therapy
    1. By Value
  7. Immunotherapy
    1. By Value
2. By Drugs
  1. Introduction
    1. Drugs By Value
  2. Temozolomide
    1. By Value
  3. Bevacizumab
    1. By Value
  4. Lomustine
    1. By Value
  5. Carmustine Wafers
    1. By Value
  6. Others
    1. By Value
3. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Clinics
    1. By Value
  4. Ambulatory Surgical Centers
    1. By Value
Canada

Europe Market Analysis

Introduction
By Treatment
1. Introduction
  1. Treatment By Value
2. Surgery
  1. By Value
3. Radiation Therapy
  1. By Value
4. Chemotherapy
  1. By Value
5. Targeted Therapy
  1. By Value
6. Tumor Treating Field (TTF) Therapy
  1. By Value
7. Immunotherapy
  1. By Value
By Drugs
1. Introduction
  1. Drugs By Value
2. Temozolomide
  1. By Value
3. Bevacizumab
  1. By Value
4. Lomustine
  1. By Value
5. Carmustine Wafers
  1. By Value
6. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Clinics
  1. By Value
4. Ambulatory Surgical Centers
  1. By Value
U.K.
1. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Surgery
    1. By Value
  3. Radiation Therapy
    1. By Value
  4. Chemotherapy
    1. By Value
  5. Targeted Therapy
    1. By Value
  6. Tumor Treating Field (TTF) Therapy
    1. By Value
  7. Immunotherapy
    1. By Value
2. By Drugs
  1. Introduction
    1. Drugs By Value
  2. Temozolomide
    1. By Value
  3. Bevacizumab
    1. By Value
  4. Lomustine
    1. By Value
  5. Carmustine Wafers
    1. By Value
  6. Others
    1. By Value
3. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Clinics
    1. By Value
  4. Ambulatory Surgical Centers
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Treatment
1. Introduction
  1. Treatment By Value
2. Surgery
  1. By Value
3. Radiation Therapy
  1. By Value
4. Chemotherapy
  1. By Value
5. Targeted Therapy
  1. By Value
6. Tumor Treating Field (TTF) Therapy
  1. By Value
7. Immunotherapy
  1. By Value
By Drugs
1. Introduction
  1. Drugs By Value
2. Temozolomide
  1. By Value
3. Bevacizumab
  1. By Value
4. Lomustine
  1. By Value
5. Carmustine Wafers
  1. By Value
6. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Clinics
  1. By Value
4. Ambulatory Surgical Centers
  1. By Value
China
1. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Surgery
    1. By Value
  3. Radiation Therapy
    1. By Value
  4. Chemotherapy
    1. By Value
  5. Targeted Therapy
    1. By Value
  6. Tumor Treating Field (TTF) Therapy
    1. By Value
  7. Immunotherapy
    1. By Value
2. By Drugs
  1. Introduction
    1. Drugs By Value
  2. Temozolomide
    1. By Value
  3. Bevacizumab
    1. By Value
  4. Lomustine
    1. By Value
  5. Carmustine Wafers
    1. By Value
  6. Others
    1. By Value
3. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Clinics
    1. By Value
  4. Ambulatory Surgical Centers
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Treatment
1. Introduction
  1. Treatment By Value
2. Surgery
  1. By Value
3. Radiation Therapy
  1. By Value
4. Chemotherapy
  1. By Value
5. Targeted Therapy
  1. By Value
6. Tumor Treating Field (TTF) Therapy
  1. By Value
7. Immunotherapy
  1. By Value
By Drugs
1. Introduction
  1. Drugs By Value
2. Temozolomide
  1. By Value
3. Bevacizumab
  1. By Value
4. Lomustine
  1. By Value
5. Carmustine Wafers
  1. By Value
6. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Clinics
  1. By Value
4. Ambulatory Surgical Centers
  1. By Value
UAE
1. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Surgery
    1. By Value
  3. Radiation Therapy
    1. By Value
  4. Chemotherapy
    1. By Value
  5. Targeted Therapy
    1. By Value
  6. Tumor Treating Field (TTF) Therapy
    1. By Value
  7. Immunotherapy
    1. By Value
2. By Drugs
  1. Introduction
    1. Drugs By Value
  2. Temozolomide
    1. By Value
  3. Bevacizumab
    1. By Value
  4. Lomustine
    1. By Value
  5. Carmustine Wafers
    1. By Value
  6. Others
    1. By Value
3. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Clinics
    1. By Value
  4. Ambulatory Surgical Centers
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Treatment
1. Introduction
  1. Treatment By Value
2. Surgery
  1. By Value
3. Radiation Therapy
  1. By Value
4. Chemotherapy
  1. By Value
5. Targeted Therapy
  1. By Value
6. Tumor Treating Field (TTF) Therapy
  1. By Value
7. Immunotherapy
  1. By Value
By Drugs
1. Introduction
  1. Drugs By Value
2. Temozolomide
  1. By Value
3. Bevacizumab
  1. By Value
4. Lomustine
  1. By Value
5. Carmustine Wafers
  1. By Value
6. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Clinics
  1. By Value
4. Ambulatory Surgical Centers
  1. By Value
Brazil
1. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Surgery
    1. By Value
  3. Radiation Therapy
    1. By Value
  4. Chemotherapy
    1. By Value
  5. Targeted Therapy
    1. By Value
  6. Tumor Treating Field (TTF) Therapy
    1. By Value
  7. Immunotherapy
    1. By Value
2. By Drugs
  1. Introduction
    1. Drugs By Value
  2. Temozolomide
    1. By Value
  3. Bevacizumab
    1. By Value
  4. Lomustine
    1. By Value
  5. Carmustine Wafers
    1. By Value
  6. Others
    1. By Value
3. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Clinics
    1. By Value
  4. Ambulatory Surgical Centers
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Glioblastoma Multiforme (GBM) Treatment Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Merck & Co. Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
Amgen Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Arbor Pharmaceuticals LLC
Karyopharm Therapeutics Inc.
Amneal Pharmaceuticals
Sumitomo Dainippon Pharma Oncology Inc. (Boston Biomedical Inc.).

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment